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Main results
We identified more than 12 studies that used antioxidants in the treatment of Friedreich ataxia, but only two small RCTs, with a combined total of 72 participants, both fulfilled the selection criteria for this review and published results. One of these trials compared idebenone with placebo, the other compared high-dose versus low-dose coenzyme Q10 and vitamin E (the trialists considered the lowdose medication to be the placebo). We identified two other completed RCTs, which remain unpublished; the interventions in these trials were pioglitazone (40 participants) and idebenone (232 participants). Other RCTs were of insufficient duration for inclusion.
In the included studies, the primary outcome specified for the review, change in a validated Friedreich ataxia rating score, was measured using the International Co-operative Ataxia Rating Scale (ICARS). The results did not reveal any significant difference between the antioxidant-treated and the placebo groups (mean difference 0.79 points, 95% confidence interval -1.97 to 3.55 points; low-quality evidence).
The published included studies did not assess the first secondary outcome, change in cardiac status as measured by magnetic resonance imaging. Both studies reported changes in cardiac measurements assessed by echocardiogram. The ejection fraction was not measured in the larger of the included studies (44 participants). In the smaller study (28 participants) , it was normal at baseline and did not change with treatment. End-diastolic interventricular septal thickness showed a small decrease in the smaller of the two included studies. In the larger included study, there was no decrease, showing significant heterogeneity in the study results; our overall assessment of the quality of evidence for this outcome was very low. Left ventricular mass (LVM) was only available for the smaller RCT, which showed a significant decrease. The relevance of this change is unclear and the quality of evidence low.
There were no deaths related to the treatment with antioxidants. We considered the published included studies at low risk of bias in six of seven domains assessed. One unpublished included RCT, a year-long study using idebenone (232 participants), published an interim report in May 2010 stating that the study reached neither its primary endpoint, which was change in the ICARS score, nor a key cardiological secondary endpoint, but data were not available for verification and analysis.
Authors' conclusions
Low-quality evidence from two small, published, randomised controlled trials neither support nor refute an effect from antioxidants (idebenone, or a combination of coenzyme Q10 and vitamin E) on the neurological status of people with Friedreich ataxia, measured with a validated neurological rating scale. A large unpublished study of idebenone that reportedly failed to meet neurological or key cardiological endpoints, and a trial of pioglitazone remain unpublished, but on publication will very likely influence quality assessments and conclusions. A single study of idebenone provided low-quality evidence for a decrease in LVM, which is of uncertain clinical significance but of potential importance that needs to be clarified. According to low-quality evidence, serious and non-serious adverse events were rare in both antioxidant and placebo groups. No non-antioxidant agents have been investigated in RCTs of 12 months' duration.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatments for Friedreich ataxia
Review question
We reviewed the evidence about the effect of antioxidants and other medicines for Friedreich ataxia.
Background
Friedreich ataxia is a rare inherited neurological condition, which first presents between 5 and 15 years of age. It initially causes clumsiness of movement, and progresses to unsteadiness in standing and walking, with wheelchair dependency by late teens or early twenties. Speech usually becomes slurred. A specific faulty gene must be inherited from each parent for the disease to develop in their child (autosomal recessive inheritance). Other major problems which can develop include a curved spine (scoliosis), foot deformity (a high arch), and heart problems, which are a cause of death in 60% of people. Friedreich ataxia has no known effective treatment. Clinical examination and laboratory tests are not very useful for assessing disease progression, and this in turn makes interpreting clinical trial results difficult.
Antioxidants are thought to reduce damage to cells from harmful 'free radicals'. Antioxidants occur naturally in foods in very low levels. Recent studies have found conflicting results about the effect that the antioxidants idebenone, coenzyme Q10 and vitamin E have on
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidant versus placebo for Friedreich ataxia The m ean change in ataxia rating score in the control groups was a 4.5-point decrease and ranged f rom 0 to -9 points 2
The m ean change in ataxia rating score in the intervention groups was 0.79 points higher (1.97 lower to 3.55 higher)
-72 (2 studies) ⊕⊕ low 3, 4 Decrease in score indicates im provem ent
Ejection fraction Follow-up: 1 year
The m ean change in ejection f raction in the control group was a 0.
64% increase
The m ean change in ejection f raction in the intervention group was 0.21% lower (5.55% lower to 5.13% higher) There were 2 adverse events leading to withdrawal (placebo group: prolonged nausea; antioxidant group: increased bowel f requency)
B A C K G R O U N D
Description of the condition
Friedreich ataxia (FA) is a rare inherited recessive disorder characterised by a slowly progressive neurological disability, but the most common recessively inherited ataxia worldwide. It was first described in 1863 by the German neurologist and pathologist Nicholas Friedreich. It has a prevalence of approximately 1 in 50,000 in European populations (Dürr 1996) . It is thought that about 50,000 individuals worldwide are affected, but more exact figures are not available. There is no biomarker or easily defined clinical marker for this small patient population (Di Prospero 2007; Pandolfo 2008) . Friedreich ataxia age of onset varies. It can present from early infancy to adulthood with unsteadiness in standing or walking. It is followed by progressive limb and gait ataxia, as well as slurred speech. Most people with Friedreich ataxia are wheelchair dependent by their late teens or early twenties. Cardiac dysfunction in the form of congestive cardiac failure and arrhythmia is common. Cardiac complications are the most common cause of death in patients with FA (59% of deaths are from a cardiac cause (Tsou 2011)). Other significant medical problems which may develop include scoliosis and pes cavus in 55%, diabetes in 12% to 30% and impaired glucose tolerance in 49% of people with Friedreich ataxia (Cnop 2012; Dürr 1996) . Mutations in theFrataxin gene (FXN) on chromosome 9q13 were found to cause Friedreich ataxia in 1996 (Campuzano 1996) . Most people with Friedreich ataxia are homozygous for expansions of a GAA repeat in the first intron of the FXN gene. Normal alleles have 40 or fewer GAA repeats while disease alleles have from 100 to more than 1700 repeats. These repeat expansions induce a packaging of the involved genomic regions into inaccessible heterochromatin structure leading to gene silencing. In rare cases, point mutations are found in heterozygosity with a GAA repeat expansion. TheFrataxin gene encodes for a small mitochondrial protein called frataxin, whose expression is reduced in Friedreich ataxia (Schulz 2000) .
Description of the intervention
Until 2009, the pharmacological treatments most commonly used in clinical trials were antioxidants, of which there were many, including pioglitazone. Since 2009, other agents have been used. The most common drugs are deferiprone, erythropoietin, and histone deacetylase inhibitors, of which there are many, including nicotinamide.
Antioxidants
Antioxidants are biological and chemical compounds that reduce oxidative damage. They are a group of organic nutrients that include vitamins. The best known antioxidants are vitamins A, C, and E, which are found in fruit, vegetables, cereals, some teas, grape seed extract, and red wine. However, the antioxidant activity levels in these foods do not reach what would be considered therapeutic levels, capable of modifying the rate of disease progression in Friedreich ataxia. Vitamin C increases lipo peroxidation by reducing Fe 3+ to Fe 2+ . This decreases the activity of respiratory complex II. Furthermore, cellular studies have indicated that ascorbic acid may increase some of the iron-associated adverse effects seen in Friedreich ataxia (Rustin 1999) . The most commonly considered antioxidant medications for Friedreich ataxia include the following. 1. Idebenone, a short chain quinone analogue that acts as a free-radical scavenger. It is a synthetic analogue of coenzyme Q10, a potent antioxidant and may act as an electron carrier in the respiratory chain. It has been used in recent studies in Friedreich ataxia.
2. Coenzyme Q10, a naturally occurring compound found in every cell in the body. It carries electrons from complexes I and II to complex III in the respiratory chain, playing a role in mitochondrial adenosine triphosphate production. It is fat soluble.
3. Vitamin E, a naturally occurring lipid soluble antioxidant. Its deficiency causes a spinocerebellar phenotype with peripheral neuropathy that clinically resembles Friedreich ataxia. 4. N-acetylcysteine, a precursor of glutathione, a natural intracellular antioxidant whose protective properties have been demonstrated in a number of cellular models. It has been used as a treatment, for example, in liver, heart, and lung disease. 5. Selegiline, a selective monoamine oxidase B inhibitor. Selegiline increases superoxide dismutase and catalase activity and probably has additional antioxidant properties. It was initially used in Parkinson's disease for presumed neuro protective antioxidant properties. Its clinical efficacy in Parkinsonism is only apparent when prescribed with levo-dopa (Drugs.com).
6. Dehydroepiandrosterone, a steroid synthesised in brain glial cells.
7. Alpha-tocopheryl quinine EPI-A0001 (A0001), a potent antioxidant and metabolic stimulator.
8. Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR) molecule that is currently licensed for treatment of diabetes mellitus. It induces the expression of enzymes involved in mitochondrial metabolism, including superoxide dismutase, which is an important antioxidant defence in nearly all cells exposed to oxygen. It is proposed that this agent could be therapeutic in neurological disease by improving the antioxidant defence mechanism. Pioglitazone crosses the blood-brain barrier in humans (Grommes 2013). A randomised control clinical trial using pioglitazone in Friedreich ataxia was completed in March 2013 (NCT00811681). 9. Some studies have used antioxidants in combination with other pharmacological treatments (Arpa 2014).
Non antioxidant treatment
The most common other pharmaceuticals that have been proposed as treatment for Friedreich ataxia are as follows:
1. Deferiprone, an iron chelator, is a small molecule that preferentially binds iron, a toxic metal, over other metals and prevents a build-up of reactive oxygen species, thereby reducing oxidative stress. Deferiprone can cross the blood-brain barrier.
2. Erythropoietin (EPO), a glycoprotein hormone produced in the kidney that principally regulates red blood cell production. Other biological functions include playing an important part in the brain's response to neuronal injury and in the wound healing process. Recombinant human erythropoietin (rHuEPO) was found to increase frataxin in open-label studies in Friedreich ataxia patients (Boesch 2007; Nachbauer 2011; Saccà 2010) . Recombinant DNA (rDNA) molecules are formed by laboratory methods of genetic recombination to bring together genetic material from multiple sources.
3. Histone deacetylase inhibitors (HDACis) modulate the level of acetylation of chromosomal proteins and other cellular targets, and can revert the silent heterochromatin to an active chromatin conformation and restore the normal function of the silenced genes (Robinson 2014). This results in a raised fraxin level, which is the underlying problem in Friedreich ataxia (Campuzano 1997) . The HDACis used to date are nicotinamide and 2-aminobenzamide (109/RG2833).
4. Resveratrol, a plant-derived compound that increased the level of frataxin in cell and mouse models of Friedreich ataxia.
5. Interferon gamma-1b, a compound currently used to treat chronic granulomatous disease and severe malignant osteopetrosis (BNF 2016).
How the intervention might work
Antioxidants are postulated to protect against oxidative stress in neuronal and cardiomyocytes, which is caused by a loss of frataxin in Friedreich ataxia. Frataxin is ubiquitous, with high levels in the central and peripheral nervous systems and in some non-neuronal tissues, such as the heart, pancreas, liver, muscle, thymus, and brown fat. Some, but not all, of these tissues are affected in Friedreich ataxia; for example, in the nervous system, primary sensory neurons, the dentate nucleus, and pyramidal tracts undergo atrophy, while other neuronal systems are much more resistant, despite similar levels of frataxin expression. When frataxin is deficient, the mitochondrial function of the cell is severely affected. There is a loss of iron sulphur proteins, respiratory chain I, II, III complexes, and aconitase. This causes a reduction in adenosine triphosphate generation. This reduction was confirmed using magnetic resonance spectroscopy on cardiac muscle (Lodi 2001) . Mitochondria also become overloaded with iron. This causes an increase in reactive oxygen species which has been verified by increased levels of plasma malondialdehyde and urinary 8-hyroxy-2-deoxyguanosine (Emond 2000) . Both respiratory chain dysfunction and oxidative stress are likely to result in cardiac or cardiomyocyte hypertrophy and neuronal cell dysfunction. Antioxidants are postulated to protect against these effects. Deferiprone is proposed to work in Friedreich ataxia by redistributing iron from the overloaded mitochondrial compartment to the cytosol (Kakhlon 2008). Using regimens suitable for patients with no iron overload, deferiprone has been associated with an imaging reduction of iron signal in the dentate nuclei of people with Friedreich ataxia as well as a reduction in neuropathy and ataxia in one open study (Boddaert 2007) . Deferiprone does not cause overall iron depletion, unlike other iron chelators, and this makes it an interesting candidate for Friedreich ataxia treatment (Pandolfo 2014). Erythropoetin, in the form of recombinant human erythropoietin (rhuEPO), has been shown in open label studies to significantly increase frataxin expression in many cells, including lymphocytes from Friedriech ataxia patients in vitro (Boesch 2007; Nachbauer 2011; Saccà 2010) . Histone deacetylase inhibitors (HDACis) work by raising the frataxin level. Herman 2006 showed that in human lymphoblastoid cells from Friedreich ataxia patients, it was possible to revert the FXN gene silencing and raise the low frataxin level. A report from the 2014 Annual American Neurology meeting further confirmed that HDACis induce increased expression of frataxin gene in the participants (Robinson 2014). Interferon gamma-1b has been found to increase frataxin expression in dorsal root ganglion neurons in treated mouse models and these models also had improved sensorimotor performance (Tomassini 2012).
Why it is important to do this review
Currently, there is conflicting evidence about the value of different treatments in Friedreich ataxia, and in particular, the value of antioxidants. Clinical trials using antioxidants in Friedreich ataxia have been ongoing since the late 1990s and have suggested that idebenone, an antioxidant, may help left ventricular hypertrophy, the most frequent heart abnormality (Buyse 2003; Hausse 2002; Mariotti 2003; Pineda 2008; Ribai 2007; Rustin 1999) . However, Ribai 2007 found that even though left ventricular mass improved, cardiac function, as measured by ejection fraction, did not improve. Artuch 2002 and Lynch 2010 did not demonstrate an improvement in cardiac measures with idebenone. Schulz 2000 treated 48 people with Friedreich ataxia with the antioxidant idebenone over an eight-week period and found a significant decrease in urinary 8-hydroxy-2-deoxyguanosine. A more recent study assessed 48 participants over six months and did not observe significant changes in the concentrations of urinary 8-hydroxy-2deoxyguanosine after idebenone treatment (Di Prospero 2007) . Quebec licensed the antioxidant idebenone from July 2008 for the treatment of Friedreich ataxia. Initial licensing was conditional upon the outcome of clinical trials (Health Canada 2009). During that period, idebenone was provided free of charge, but Quebec withdrew the licence in April 2013. In November 2008, the European Medicines Agency refused marketing authorisation for idebenone in Europe (EMA 2009). The US Food and Drugs Administration has never authorised idebenone for use in Friedreich ataxia. This is the second update of a review first published in 2009 and previously updated in 2012 (Kearney 2009; Kearney 2012).
O B J E C T I V E S
To assess the effects of antioxidants and other pharmacological treatments for Friedreich ataxia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) or quasi-RCTs of antioxidants and other pharmacological treatments for Friedreich ataxia. Quasi-RCTs are studies that use semi-systematic methods of allocation to treatments, for example, alternation, or allocation by case record number of date of birth.
Types of participants
Participants with genetically-confirmed Friedreich ataxia at all stages of their illness, both sexes, and any age.
Types of interventions
Any pharmacological treatment compared with any other pharmacological treatment, placebo, or no treatment. We included any form of treatment considered to have an antioxidant effect (including vitamins) as well as other pharmacological treatments. We analysed antioxidants as a group. We would have performed additional subgroup analyses of individual antioxidants if the review had included sufficient trials. We would have considered other pharmacological treatments individually, or within therapeutic groups, as appropriate.
Types of outcome measures
Primary outcomes
Change in score on validated Friedreich ataxia rating scales after 12 months of treatment. We considered the following scales:
• Scale for the Assessment and Rating of Ataxia (SARA);
• Friedreich Ataxia Rating Scale (FARS); • International Cooperative Ataxia Rating Scale (ICARS).
An absolute reduction in these scores indicates improvement. Friedreich ataxia is a slowly progressive disorder. There is no biochemical or simple clinical measure of progression. Current scoring systems are composite scores of disability and impairment measures: the ataxia rating scales. The SARA, which is primarily, but not exclusively, an impairment scale, has been validated for both spinocerebellar ataxia and Friedreich ataxia (Bürk 2009), and is the preferred scale in the most recent trials. The FARS was validated in 2006 (Fahey 2006) . The ICARS was developed for neurological conditions by a committee of the World Federation of Neurology in 1997 and was validated (Trouillas 1997). In future, pure disability or impairment scales would be preferable as primary outcome measures in the review. If these are used in trials, currently reported mixed scales will become secondary outcome measures.
Secondary outcomes
We also assessed secondary outcomes after 12 months of treatment. 1. Change in cardiac measures: ejection fraction, end-diastolic interventricular septal thickness (IVSTd) and left ventricular mass (LVM), as measured by cardiac magnetic resonance imaging (cMRI).
2. Change in cardiac measures: ejection fraction, end-diastolic IVSTd, LVM as measured by echocardiogram.
3. Improvement in any validated quality of life score. 4. Mild adverse effects (medication continued). 5. Severe adverse affects (defined as leading to cessation of medication).
6. Survival. There has been much debate about how best to quantify the cardiomyopathy in Friedreich ataxia. Weidemann 2012 reviewed the cardiac status of 205 people with Friedreich ataxia in detail. The study found that IVSTd, as measured by echocardiogram, was a reliable predictor of LVM when the results were correlated with those from cMRI. The latter has been shown to be the more sensitive and accurate in determining the severity of cardiomyopathy in Friedreich ataxia (Grothues 2002) . Cardiac assessment is complicated, as there is not a single cut-off point for defining normal versus abnormal IVSTd in this group of people. The clinical phenotype varies, disease progression is variable, and with the passage of time, people with Friedreich ataxia develop a worsening cardiomyopathy. People with Friedreich ataxia commonly develop myocar-dial fibrosis with a subsequent decrease in IVSTd, which could be mistaken for a positive treatment effect (Weidemann 2012). An ejection fraction of 55% or higher is considered normal (Mayo Clinic 2015) . For this review, we selected ejection fraction as the principal criterion for defining the severity of cardiomyopathy and measuring heart function in Friedreich ataxia (Weidemann 2012), in conjunction with IVSTd.
Search methods for identification of studies
Electronic searches
We searched The Cochrane Neuromuscular Specialised Register (29 February 2016) , CENTRAL (29 February 2016 in the Cochrane Register of Controlled Trials Online (CRSO)), MED-LINE (January 1966 to February 2016), EMBASE (January 1980 to February 2016), CINAHL Plus (January 1937 to February 2016), ORPHANET (1990 to September 2015 , and TRIP (1998 to September 2015). We have presented the detailed search strategies in the appendices: Appendix 1 (Cochrane Neuromuscular Specialised Register), Appendix 2 (CENTRAL), Appendix 3 (MEDLINE), Appendix 4 (EMBASE), Appendix 5 (CINAHL Plus), Appendix 6 (OR-PHANET) and Appendix 7 (TRIP). We decided in advance that if we included clinical trials conducted prior to 1996 (genetic diagnosis of Friedreich ataxia became avail-able in 1996), we would exclude their results from further analysis if genetic confirmation had not been subsequently carried out. As searching AMED, LILACS and PEDRO produced no useful results, we did not search these databases after the first version of this review.
Searching other resources
Three review authors inspected the reference lists of all papers selected from the searches. We performed a search of the references listed in the published studies, reviews, and relevant conference proceedings. We also considered studies in languages other than English for inclusion. We consulted the Clinical Trials Registry of the U.S. National Institute of Health (Clinical trials) to identify additional trials that had not yet been published. We searched the World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/) (last search March 2016). We obtained the latest results from the RCTs by searching conference proceedings, canvassing colleagues, and reviewing the websites of the patient organisations, Friedreich Ataxia Research Alliance and euro-ataxia.
Data collection and analysis
We conducted data collection and analysis in accordance with the Cochrane Handbook for Systematic Reviews of Intervention ( Higgins 2011). Figure 1 shows the flow of information through the different phases of the systematic review. 
Selection of studies
Three review authors (MK, RO, and MF) independently checked titles and abstracts obtained from literature searches to identify potentially relevant trials for the review. They obtained the full text of all potentially relevant studies for independent assessment. The review authors resolved disagreements about inclusion criteria by discussion.
Data extraction and management
Two authors (MK and RO) independently extracted data from the included studies onto a specially designed data extraction form. They resolved disagreements by discussion. Review authors sought further data from the lead author of Cooper 2008, as the study report provided outcome data at two years rather than at one year as specified in our protocol.
Assessment of risk of bias in included studies
We assessed risk of bias in the included studies using the Cochrane 'Risk of bias' tool, considering the domains of random sequence generation, allocation concealment, blinding (investigators, participants, and outcome assessors), incomplete outcome data, selective outcome reporting and other sources of bias. We made a judgment on each of these criteria, rating studies as at 'High risk of bias', 'Low risk of bias' or 'Unclear risk of bias' for each criterion (Figure 2 ).
Figure 2. Methodological quality summary: review authors' judgments about each methodological quality
item for each included study. We could not evaluate attrition bias in the unpublished studies.
Measures of treatment effect
We reported risk ratios (RRs) with 95% confidence intervals (CIs) for binary outcomes such as adverse events. For continuous outcomes, such as ICARS scores, ejection fraction, IVSTd, and LVM, we calculated mean differences with 95% CI. If trials had reported the same outcome using different measurement tools, we would have combined data using standardised mean differences and 95% CIs.
We analysed all the primary and secondary outcomes under consideration whenever the data allowed.
Unit of analysis issues
The unit of analysis was a participant. To prevent unit-of-analysis issues related to repeated measures, we chose to analyse outcome data after 12 months of treatment.
Dealing with missing data
Since completion of the previous review update in 2012, Dr Cooper provided raw data on the change in the ICARS score and IVSTd after 12 months (Cooper 2008) . We completed the data extraction form and determined that we could include this study in this updated review. We sought details of the primary outcome of Mariotti 2003 from Dr Mariotti in 2009, who supplied the mean, standard deviation and P value for ICARS scores at the start and after 12 months for both the placebo and the treatment groups. We included these details on the data extraction sheet for the initial publication of this review in 2009. We sought details of ejection fraction measurements for the 2015 update and the raw data on these measurements were supplied. Weidemann 2012 was completed in 2009, We contacted the trialists several times, and on our last contact in January 2016, the lead investigator, Dr Frank Weideman, responded to our query, advising that the manuscript was in preparation. We contacted the authors of NCT00811681 in January 2016. Dr Pierre Rustin responded by email, and told us that the clinical trial had missed its primary endpoint, change in neurological score.
Assessment of heterogeneity
We used the I 2 test for heterogeneity. We considered that an I 2 greater than 50% suggested that variations in the effect estimates of the different studies were due to differences between trials rather than to chance alone. We initially used a fixed-effect model and repeated the analysis with a random-effects model.
Assessment of reporting biases
The search strategies covered multiple sources without language or publication restrictions. We were alert to the possibility of duplication of studies. We did not produce a funnel plot, as the review included too few studies for an analysis of small study effects to be meaningful (Sterne 2011).
Data synthesis
We performed statistical analyses of the data using Review Manager 5 (RevMan 5). We combined data from primary studies of antioxidants versus placebo and reported the results of analyses using a random-effects model.
'Summary of findings' table
We created a 'Summary of findings' table for each comparison using the following outcomes: change in ICARS score, change in cardiac measures (ejection fraction, IVSTd, and LVM), severe adverse events, and survival. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), using GRADEpro software. We justified all decisions to downgrade or up-grade the quality of studies using footnotes, and we made comments to aid readers' understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was not relevant. We investigated heterogeneity by inspecting trials and the forest plot. We reviewed the clinical and methodological characteristics of the included studies.
Sensitivity analysis
Sensitivity analysis was not relevant.
R E S U L T S Description of studies
Results of the search
The numbers of papers found by the update searches run by the Cochrane Neuromuscular Information Specialist were: Cochrane Neuromuscular Specialised Register = 34, CENTRAL = 24, MEDLINE = 64, EMBASE = 41, CINAHL Plus = 33, DARE = 6, HTA = 1, for a total of 203 new records (181 after deduplication). The review authors identified 135 new records in TRIP, 1 new record in ORPHANET, and 79 additional records through searching other sources. The review authors identified eight studies (reported in nine full-text articles) to be studied in detail for eligibility (see PRISMA flow chart Figure 1 ). From these, we identified no new studies through the searches for this update. To the one study included in the last version of this review, we added three other studies previously identified as either awaiting classification or ongoing.
Included studies
In the initial review and first update, we included one study (Mariotti 2003) , and one other study awaited classification (Cooper 2008) . As a result of information from the trial author, we included Cooper 2008 in this update of the review. We reviewed the information on Weidemann 2012 and NCT00811681 and found that they also met our selection criteria. Cooper 2008 initially included 50 participants with geneticallyconfirmed homozygous expansion for Friedreich ataxia. The trial compared high-dose and a very low-dose of coenzyme Q10 and vitamin E antioxidants over a two-year period. The trial authors considered the very low dose coenzyme Q10 and very low dose vitamin E as placebos. The authors justified this, citing recruitment difficulties for a trial involving a placebo group.
Mariotti 2003 compared the antioxidant idebenone 5 mg/kg to placebo in 29 participants with genetically-confirmed homozygous expansion for Friedreich ataxia. In all participants, the condition had been present for over 10 years. Eighteen participants were wheelchair dependent at the onset of the study. In Weidemann 2012, 232 participants were randomised to receive idebenone or placebo (dosage adjusted for weight) and 205 provided outcome data. At the planning stage of this study, the trialists decided to enrol a significant number of ambulatory participants, as defined by a person who could walk at least 10 meters with or without a walking aid but without the help of an accompanying person. NCT00811681 was a double-blind clinical trial of pioglitazone over a two-year period, involving 40 participants with confirmed Freidreich ataxia. The pioglitazone dose was increased to a maximum of 45 mg/day and the primary endpoint was change in ataxia rating scale score (ICARS) after two years. 
Excluded studies
There were five excluded studies, described in six reports (two of the reports were from the same study (Lynch 2010)). We excluded these trials because they did not fulfil the duration criterion of 12 The main aim of the study was to determine safety and tolerability. Changes in 9-hole peg test, timed 25-foot walk, low-contrast letter acuity, ICARS, and FARS scores were secondary outcomes. Cardiac measures and activities of daily living were also assessed. Mariotti 2010 was a randomised, double-blind, placebo-controlled, dose-finding trial. Sixteen adults with Friedreich ataxia received erythropoietin in three consecutive cycles intravenously (20,000 to 40,000 units every two weeks) or placebo over a sixmonth period, followed by a six-month phase of subcutaneous treatment. All patients were also treated with idebenone (5 mg/kg/ day). The study assessed safety and frataxin levels in lymphocytes. Schöls 2005 was a randomised, placebo-controlled, cross-over study comparing L-carnitine (3 g daily), creatine (6.75 g daily) and placebo over a four-month period. Participants were 16 ambulant adults with genetically-confirmed Friedreich ataxia. The trialists assessed "mitochondrial ATP production measured as phosphocreatine recovery by 31 Phosphorus magnetic resonance spectroscopy," ICARS scores, and cardiac hypertrophy by echocardiography.
Studies awaiting classification
There are no studies awaiting classification.
Ongoing studies
None of the several ongoing studies in Friedreich ataxia fulfil the selection criteria set by this review as being an RCT of at least one year's duration.
Risk of bias in included studies
The review authors' 'Risk of bias' judgements for the included studies are summarised in Figure 2 . See Characteristics of included studies for detailed assessments of each study.
Allocation
The two included published studies provided sufficient detail of the randomisation of participants to consider them probably at low risk of bias from sequence generation and allocation concealment.
Blinding
Cooper 2008 reported that participants were blinded until the end of the trial and that the placebo medication was indistinguishable from the active medication. The Mariotti 2003 manuscript did not mention whether participants were blinded but the contact author stated in an email that the assessors of the primary and secondary outcomes were blind to the participants' assignment.
Incomplete outcome data
In the Cooper 2008 study, six of the original 50 participants withdrew, three from high dose group and three from the low dose group. In the Mariotti 2003 study one participant withdrew from the placebo group.
Selective reporting
Trial protocols were unavailable for Cooper 2008 and Mariotti 2003, therefore, it is not possible on the basis of the published reports alone to determine whether all expected outcomes were reported. For each trial, investigators provided raw data for the outcomes of interest in the review. The unpublished but completed study Weidemann 2012 represented a high risk of reporting bias. We assessed NCT00811681 as unclear.
Other potential sources of bias
In Mariotti 2003, the proportion of ambulant versus wheelchairdependent participants was different in the intervention and placebo groups. Cooper 2008 did not provide this information.
In Cooper 2008, the authors reported no conflict of interest. Mariotti 2003 made no reference to conflicts of interest. Pooling data from the two trials, the MD was 0.79 points, 95% CI -1.97 to 3.55 (N = 72). We considered the evidence as low quality, downgrading for heterogeneity (Chi² = 5.36, df = 1 (P = 0.02); I² = 81%) (Analysis 1.1 and Summary of findings for the main comparison). Changes in ICARS and FARS scores from baseline to week 52 were both outcomes in Weidemann 2012. The study sponsors, Santhera, reported in a press release that "the primary endpoint of the study, mean change in the International Cooperative Ataxia Rating Scale (ICARS) score from baseline, did not detect any significant difference between the active dose arms and placebo" and secondary endpoints "including the proportion of patients improving on ICARS score (responder analysis) and change in the Friedreich's Ataxia Rating Scale also did not show statistically significant differences between the placebo and active dose groups". These statements are consistent with the findings from included studies, but data were not available to the review authors for independent analysis. NCT00811681 measured the change in ataxia rating scales as measured by ICARS and FARS every six months over a two-year period. We were unable to obtain data for analysis.
Effects of interventions
Secondary outcome measures: change in cardiac measure
Change in cardiac status using cMRI was not measured in Cooper 2008 or Mariotti 2003, but both studies assessed change in cardiac status using echocardiogram.
Change in ejection fraction
Ejection fraction data were only available for Mariotti 2003. None of the participants in Mariotti 2003 had "pathologic ejection fraction at baseline", as the ejection fraction remained above 50% in all trial participants over the year of follow-up. Ejection fraction increased by 0.64% in the placebo group and 0.43% in the antioxidant group, a mean difference (MD) of -0.21% (95% CI -5.55 to 5.13) (Analysis 1.2). We assessed the quality of the evidence as very low. Cooper 2008 measured fractional shortening at 12 months rather than ejection fraction; the latter is considered to be a more accurate reflection of heart function (Mayo Clinic 2015). We were unable to obtain fractional shortening data for Cooper 2008.
Change in interventricular septal thickness as measured by echocardiography
Cooper 2008 and Mariotti 2003 measured change in IVSTd, in which a decrease indicates improvement. The scores revealed a small difference between the antioxidant treated groups and the placebo groups at 12 months in favour of idebenone in Mariotti 2003. In Cooper 2008, there was no improvement. The MD (mm) of the combined measures was -0.65 (95% CI -2.00 to 0.70, N = 72, random-effects) in favour of antioxidant treatment (Analysis 1.3). We considered this evidence as very low quality because of risk of bias, marked statistical heterogeneity (I 2 statistic = 74%), and inconsistency (one trial shows a strong effect, the other none) (Analysis 1.3; Summary of findings for the main comparison). The CIs are wide, including both the possibility of change that might be clinically important and no effect.
Change in left ventricular mass
Results for left ventricular mass were available from Mariotti 2003. Left ventricular mass increased by 16.28 g (SD 29.37) in the placebo group and decreased by 14 g (SD 32.75) in the antioxidant group (MD -30.30 g, 95% CI -53.34 to -7.26, in favour of the antioxidant) (Analysis 1.4). There was a 10.7% (P = 0.01) increase in left ventricular mass after 12 months of treatment in the placebo group and a 5.6% decrease in the idebenone-treated group after 12 months of treatment. The MD was 16.37% (95% CI 2% to 31%). The potential importance of these results needs to be clarified in view of the fact that people with Friedreich ataxia commonly develop myocardial fibrosis with a subsequent decrease in LVM, which could be mistaken for a positive treatment effect.
The press release reporting the failure of Weidemann 2012 to reach its endpoints reported "no difference between the active and placebo groups in the key cardiological secondary endpoint assessing a combination of anatomical and functional cardiac parameters". We were unable to obtain data for analysis. See Characteristics of included studies for details of cardiac measures listed in the trial registry entry. Cardiac outcomes in NCT00811681 were not fully described in the clinical trials registry entry.
Improvement in quality of life score after 12 months
Not assessed by Cooper 2008 or Mariotti 2003. Change in quality of life scale measured by the Short Form 36 (SF-36) score after 12 months of treatment was among the listed outcomes in NCT00811681. No data were available.
Mild adverse effects
In Cooper 2008, the authors reported the intervention to be well tolerated and provided details of withdrawals, but did not specifically report the occurrence of mild adverse events. In Mariotti 2003, one participant experienced occasional tachycardia, which did not require treatment modification (Analysis 1.5).
Severe adverse effects
In Cooper 2008, one participant in the placebo group withdrew due to prolonged nausea, and one participant in the treatment group withdrew due to increased bowel frequency. In Mariotti 2003, there were no severe adverse effects due to idebenone or placebo.
One of the placebo participants in Mariotti 2003 died during the study as a result of diabetic ketoacidosis five months after enrolment. The trial authors considered the death to be unrelated to the clinical trial.
Survival
Survival was not an outcome in the included studies.
D I S C U S S I O N
Summary of main results
Effectiveness of pharmacological treatments versus placebo
Neither of the published included studies showed that antioxidants were effective for treating Friedreich ataxia using the primary outcome, change in the validated Friedreich ataxia neurological scale, International Cooperative Ataxia Rating Scale (ICARS; Cooper 2008; Mariotti 2003) . The included studies showed contradictory evidence in the secondary outcome, change in interventricular septal thickness as measured by echocardiography. Mariotti 2003 (28 participants) did show a significant change in left ventricular mass (LVM). This is of uncertain clinical significance, but of potential importance that needs to be clarified. Among the secondary cardiac outcomes, change in ejection fraction using echocardiogram was not measured in the Cooper 2008 study. Ejection fraction was measured in Mariotti 2003, but was normal at the outset of the study, so was not likely to demonstrate change after 12 months' treatment. Results confirmed this. Both reported studies measured change in end-diastolic interventricular septal thickness (IVSTd). There was no improvement in IVSTd in Cooper 2008. In Mariotti 2003, it showed a small improvement in favour of the antioxidant group. When we reviewed this result, we considered that in the absence of any improvement in ejection fraction, the improvement in IVSTd was of no clear clinical significance, although the result was too imprecise to rule out the possibility of an effect. We were not successful in our attempts to obtain data from two unpublished studies, which involved a combined total of approximately 272 participants.
Overall completeness and applicability of evidence
The low-or very low-quality evidence in this review is currently insufficient to support or refute an effect of antioxidants in Friedreich ataxia. The authors felt that all relevant studies were identified but the evidence is incomplete, as Weidemann 2012 and NCT00811681 had no published results as of May 2016. Santhera, the sponsors of Weidemann 2012, published an interim report in May 2010 stating that the study had failed to reach its primary endpoint, which was change in ICARS score (Santhera 2010). The company also reported no change in secondary endpoints Friedreich Ataxia Rating Score (FARS), and cardiac parameters. The results of these unpublished trials, particularly Weidemann 2012, which involved 232 participants with Friedreich ataxia, represent important missing data. For years, idebenone was available to some people with Friedreich ataxia free of charge, while others had to pay for it. After the European Medicines Agency refused marketing authorisation for idebenone, several European countries and some private insurance companies reviewed their policies on reimbursement and no longer supply this medication to people with Friedreich ataxia (EMA 2009). The evidence seems to suggest that idebenone is not effective, and this is supported rather than refuted by the unpublished study (Weidemann 2012).
We identified no trials of non-antioxidant agents eligible for inclusion in the review.
Evidence from excluded studies
We limited this review to studies at least a year long, as shorter studies in this slowly progressive condition are unlikely to demonstrate clinical benefit. As this potentially excludes short-term trials signalling clinical efficacy, we briefly described excluded studies here as they have helped considerably to add to the body of knowledge about clinical trials in Friedreich ataxia. Di Prospero 2007 was a six-month, open-label dose-escalation trial involving 48 people with genetically-confirmed Friedreich ataxia. Higher doses of idebenone led to a proportional increase in plasma levels and were well tolerated. One child on a high dose of idebenone experienced neutropenia, which recovered when treatment was stopped. Overall, ICARS, FARS, and total activity of daily living (ADL) scores did not improve with idebenone. Improvement in ICARS scores but not FARS or ADL scores showed dose dependence and the difference from placebo was statistically significant at the higher doses. The subgroup of ambulant but symptomatic participants (baseline ICARS score more than 10 but less than 54), showed improvement in ICARS but not in FARS or ADL scores. Lynch 2010 reported that idebenone did not alter neurological function in Friedreich ataxia after six months of treatment. It also demonstrated that the sensitivity of the ataxia rating scales to change is limited, and suggested that in future studies, inclusion of a higher percentage of ambulant participants would be desirable. Idebenone did not decrease left ventricular hypertrophy or improve heart function in this study. Recombinant human erythropoietin (rHuEPO) was used in two RCTs, which found acceptable safety and tolerability of rHuEPO derivatives in Friedreich ataxia, but did not find any increase in frataxin levels or improvement in the clinical condition of participants over a two-week RCT (Boesch 2014), or over the six-month period in Mariotti 2010. There is rationale for deferiprone as a therapy for Friedreich ataxia; however, its safety and appropriate dosing need to be assessed prior to another large scale trial. Pandolfo 2014 was a six-month study involving 74 randomised adults and children with Friedreich ataxia. A dose of 20 mg/kg/day was well tolerated, whereas 40 mg/kg/day produced a worsening of ataxia scores (ICARS and FARS). The highest dose, 60 mg/kg/day dose was discontinued as a precautionary measure, because two participants experienced a worsening of ataxia. Ataxia in the placebo group did not deteriorate over the six-month period and this prevented the researchers from detecting any potential protective effect of deferiprone. Left ventricular mass decreased in treatment versus placebo arms, but the clinical significance of this is unclear. The trial produced inconclusive efficacy results, with no improvement over placebo at 20 mg/day, but it was too short to rule out an effect. Based on subgroup analyses, the trial authors considered that lower doses warranted further investigation. A cross-over trial comparing L-carnitine (3 g daily in three doses), creatine (6.75 g daily in three doses), and placebo over a fourmonth period among 16 ambulant adults with genetically-confirmed Friedreich ataxia, found that neither echocardiographic data nor ICARS scores demonstrated an improvement over baseline or placebo (Schöls 2005) .
Evidence from other studies
A histone deacetylase inhibitor (HDACi),109/RG 2833 was welltolerated in a phase 1 trial (Soragni 2014), but Robinson 2014 reported that two drug metabolites persisted in the serum for hours after the compound was broken down, one a suspected cardiotoxin and the other a suspected carcinogen. This led the group to begin developing related compounds that penetrate the blood-brain barrier but which are without these effects. Libri 2014 used the HDACi nicotinamide in an open-label, dose-escalation study over an eight-week period. This study showed a sustained improvement in frataxin concentration over the course of the treatment. Gene therapy research in Friedreich ataxia has been ongoing for the last 10 years. A GAA-expanded frataxin genomic DNA reporter model of Friedreich ataxia has been developed. which would lead the way to identification of novel therapies (Lufino 2013). In Friedreich ataxia, protection for nerve cells would be a priority.
Kemp 2011 looked to see if bone marrow-derived cells might be able to protect cerebellar neurons in vitro. He demonstrated "that normal human mesenchymal stem cells (MSCs) induce both an increase in frataxin gene and protein expression in Friedreich ataxia fibroblasts via secretion of soluble factors". The most recent study, Perdomini 2014, reported that cardiomyocytes from mice with severe energy failure and ultra structural disorganisation, can be rapidly rescued and remodelled by gene therapy. This established pre-clinical proof of concept for the potential of gene therapy in treating Friedreich ataxia cardiomyopathy. Many of the studies referenced in this section have been based at multiple centres in different countries and continents. In recent years, clinicians have been keen to organise double-blind clinical trials. Patient organisations have come together internationally to make patient recruitment for clinical trials possible.
Quality of the evidence
The quality of the evidence from the results of the two included and reported studies was low for the validated Friedreich ataxia neurological scale score, ICARS, and low or very low for other outcomes. As Friedreich ataxia varies considerably in genetic severity, has a varying age of onset from 5 to 60 years, has a variable clinical progression, and is heterogeneous in its clinical features, much of the recent research has focused on finding an accurate measure of disease progression (Bürk 2009). Lynch 2010 revealed that the sensitivity of the neurological examination when using the ICARS and the FARS was limited, and each scale had a variety of other drawbacks. When the participants are wheelchair-dependent, posture and gait scores in the ICARS are redundant, leading to a sudden, significant deterioration in the person's ICARS score when they become wheelchair-dependent, followed by a period where there is almost no change in the score, which is know as a ceiling effect. In the planning stage of Weidemann 2012, an effort was made to eliminate this ceiling effect by enrolling a significant percentage of ambulatory participants. Weidemann 2012 reported that 51.8% of participants were ambulatory. In Mariotti 2003, 37% were ambulatory, that is, 11 out of 29 participants. A collaborative project funded by the European Commission, called the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS; www.e-facts.eu), is testing the validity of ataxia rating scales in a four-year prospective study from 2012 to 2016. It reviews its Friedreich ataxia participants on an annual basis. An American network, Collaborative Clinical Research Network in Friedreich Ataxia (CCRN in FA; www.curefa.org), is testing the validity of the FARS for measuring long-term follow-up in Friedreich ataxia. As a result of the different variables in design and implementation in the included studies, which we assessed as a potential risk of bias, we downgraded the quality of the evidence for change in the ICARS score. The evidence published in the included studies was direct. There was significant heterogeneity in the study participants and considerable inconsistency in the results for change in the cardiac measure, interventricular thickness, and as a result we found it necessary to downgrade the quality of evidence for these outcomes. As there were so few participants (N = 72), only two of whom experienced events, we downgraded the results due to imprecision for the outcomes mild adverse events and severe adverse events. The larger of the two unpublished studies appeared likely to strengthen a finding of no effect for idebenone on both neurological (the ICARS and FARS) and "anatomical and functional cardiological parameters" (Weidemann 2012). On this basis, we chose not to downgrade the evidence for publication bias, although these results were mentioned in a press release and not available for verification.
Potential biases in the review process
There may be some potential for bias in this review process as there were changes to the protocol. These included additions and deletions to the outcomes, as reported in Differences between protocol and review. None of these changes were made as a result of the findings of the included studies but rather to improve the structure of the review. We are confident that we have identified all clinically relevant trials, as we conducted a comprehensive search of all published literature and clinical trials registers for potentially relevant clinical trials and three of the review authors regularly attend international conferences on Friedrieich ataxia.
As the review includes data from only two small RCTs, it is possible that our methods have not detected all rare and serious adverse events. This review defines severe adverse events as those leading to withdrawal, which has been adequate for describing serious adverse events in currently included trials. We will widen our definition to also include adverse events that are fatal, life threatening, or require prolonged hospitalisation in future updates, if they are measured in newly included studies.
Agreements and disagreements with other studies or reviews
Some open-label trials of idebenone found an improvement in cardiac measures (Buyse 2003; Mariotti 2003; Pineda 2008; Ribai 2007; Rustin 1999) , but others, Lynch 2010, a six-month RCT and Artuch 2002, did not. Lynch 2010 found that idebenone at similar or higher doses than those that were used in Mariotti 2003 did not improve ejection fraction over a period of six months, in participants with Friedreich ataxia. As mentioned previously, we did not include Lynch 2010 in the review owing to its short duration.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Low-quality evidence from the two small, published, included randomised controlled trials neither supported nor refuted an effect from antioxidants (idebenone, or a combination of coenzyme Q10 and vitamin E) on the neurological status of people with Friedreich ataxia, measured with a validated neurological rating scale.
A large unpublished study of idebenone that reportedly failed to meet neurological endpoints, and a trial of pioglitazone remain unpublished, but on publication will very likely influence quality assessments and conclusions. Cardiac changes were based on low-and very low-quality evidence of uncertain clinical significance. According to low-quality evidence, serious and non-serious adverse events were rare in both antioxidant and placebo groups.
Other classes of agents have not been tested in clinical trials eligible for inclusion in this review.
Implications for research
Publication of data from unpublished trials is highly desirable, as important data may be missing from this review. The clinical importance of observed cardiac changes with antioxidants might warrant further investigation. Future studies might also investigate whether pharmacological interventions such as antioxidants have any complementary or adjunctive role in the treatment of Friedreich ataxia.
Friedreich ataxia is a rare, slowly progressive disorder. Researchers have not yet defined a suitable clinical marker or biomarker to assess disease progression. Clinical assessment becomes even more difficult when the patient is wheelchair-dependent. In view of these factors, and in order to evaluate the effects of other pharmacological treatments in Friedreich ataxia, we need large, placebocontrolled RCTs of 12 months' duration, using clinical scales that are both valid and responsive to change
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Three of the four authors inspected the list of potentially relevant studies.
We did not search the NORD databasefor this or the previous update.
As searching AMED, LILACS, and PEDRO produced no useful results, we did not search these databases for the 2015 update.
We included a 'Summary of findings' table. We added a PRISMA flow chart in the 2012 update to show the study selection process.
In the 2015 update, we changed the primary outcome to Change in validated Friedreich ataxia neurological score such as:
